August 4, 2021 -- Tachyon Therapeutics and antibody discovery company AbCellera are teaming up to develop a first-in-class therapeutic antibody targeting the secreted extracellular protein left-right determination factor 1 (LEFTY1), which is expressed in advanced cancers.
The LEFTY1 target is a signaling regulator of the transforming growth factor-beta (TGF-β) superfamily, which controls many cellular functions, including proliferation and apoptosis. Tachyon scientists discovered that LEFTY1 suppresses key pathways to promote long-term proliferation of normal and malignant mammary epithelial cells. Since then, the company has been exploring the targeting of LEFTY1 to control growth and self-renewal of cancer stem cells, according to the firms.
Per the agreement, AbCellera will get milestone payments and royalties for successful candidates and has an option to invest in development to reap a bigger share of sales.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
